{Reference Type}: Multicenter Study
{Title}: Comparison of the clinical features of HIV-positive and HIV-negative hosts infected with Talaromyces marneffei: A multicenter, retrospective study.
{Author}: Qiu Y;Liu AL;Huang J;Zeng W;Yang ZM;Fang GN;Li Y;Zhang YZ;Liang JK;Liu J;Liao SH;Cheng XX;Chen YJ;Ye F;Li ZT;Zhang JQ;
{Journal}: Int J Infect Dis
{Volume}: 132
{Issue}: 0
{Year}: 2023 Jul 17
{Factor}: 12.074
{DOI}: 10.1016/j.ijid.2023.04.398
{Abstract}: <B>OBJECTIVE: </B>Talaromyces marneffei is an emerging pathogen, and the number of infections in HIV-negative individuals is rapidly increasing. Nevertheless, there is no sufficient comprehensive report on this issue, and awareness needs to be raised among clinicians.<BR><B>METHODS: </B>We analyzed the differences in the clinical data of patients who are HIV-negative and HIV-positive with Talaromyces marneffei infection (TMI) from 2018 to 2022.<BR><B>RESULTS: </B>A total of 848 patients were included, among whom 104 were HIV-negative. The obvious differences between the HIV-positive and HIV-negative groups were as follows: (i) the patients who are HIV-negative were older and more likely to exhibit cough and rash, (ii) the time in days from symptom onset to diagnosis among patients who are HIV-negative was longer, (iii) the laboratory findings and radiological presentations seemed more severe in patients who are HIV-negative, (iv) differences were observed regarding the underlying conditions and co-infection pathogens, and correlation analysis showed that correlations existed for many indicators, (v) and persistent infection was more likely to occur in patients who are HIV-negative.<BR><B>CONCLUSIONS: </B>TMI in patients who are HIV-negative differs from that in patients who are HIV-positive in many aspects, and more investigations are needed. Clinicians should be more aware of TMI in patients who are HIV-negative.